Indoco Remedies Fact Sheet, Indoco Remedies Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indoco Remedies Fact Sheet    (INDOCO)


Discover Now: One Stock for Potentially Life-changing Gains


Here is the latest financial fact sheet of Indoco Remedies. For more details, see the Indoco Remedies quarterly results and Indoco Remedies share price and chart. For a sector overview, read our pharmaceuticals sector report.

INDOCO REMEDIES Price History

Price Rs 359.0
Mkt Cap Rs m 33,091
Vol '000 18.7
P/E X 84.3
P/CF X 30.4
EPS (TTM) Rs 4.3
% ch % 0.2
No. of shares m 92.18
% ch week % 8.9
% ch 1-mth % 25.5
% ch 12-mth % 55.9
52 week H/L Rs 377.2/190.0
(As on May 7, 2021 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

INDOCO REMEDIES Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
INDOCO REMEDIES EQUITY SHARE DATA
High Rs162378412360317 
Low Rs55131263249178 
Sales per share (Unadj.) Rs79.593.0109.4116.6113.1 
Earnings per share (Unadj.) Rs6.39.08.98.44.5 
Diluted earnings per shareRs6.39.08.98.44.5 
Cash flow per share (Unadj.) Rs9.614.115.515.211.8 
Dividends per share (Unadj.) Rs1.401.601.601.601.00 
Adj. dividends per shareRs1.401.601.601.601.00 
Dividend yield (eoy) %1.30.60.50.50.4 
Book value per share (Unadj.) Rs49.657.362.670.773.2 
Adj. book value per shareRs49.657.362.570.773.2 
Shares outstanding (eoy) m92.1592.1592.1592.1592.15 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x1.42.73.12.62.2 
Avg P/E ratio x17.228.337.936.455.5 
P/CF ratio (eoy) x11.218.021.820.021.0 
Price / Book Value ratio x2.24.45.44.33.4 
Dividend payout %22.217.818.019.122.4 
Avg Mkt Cap Rs m9,98923,43831,08728,08322,830 
No. of employees `000NANA5.76.05.5 
Total wages/salary Rs m1,2951,4001,8192,1672,209 
Avg. sales/employee Rs ThNMNM1,762.41,780.61,910.1 
Avg. wages/employee Rs ThNMNM318.0359.0405.0 
Avg. net profit/employee Rs ThNMNM143.3127.775.5 
INDOCO REMEDIES INCOME DATA
Net Sales Rs m7,3268,57010,08110,74810,419 
Other income Rs m1817164047 
Total revenues Rs m7,3448,58710,09710,78710,466 
Gross profit Rs m1,2041,6551,7041,5651,349 
Depreciation Rs m309471607633677 
Interest Rs m18910612462235 
Profit before tax Rs m7231,096989909484 
Minority Interest Rs m-10000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m14326717013972 
Profit after tax Rs m580828819771412 
Gross profit margin %16.419.316.914.612.9 
Effective tax rate %19.824.417.215.315.0 
Net profit margin %7.99.78.17.24.0 
INDOCO REMEDIES BALANCE SHEET DATA
Current assets Rs m3,0463,8904,6465,7215,373 
Current liabilities Rs m2,0222,9263,6413,9044,157 
Net working cap to sales %14.011.310.016.911.7 
Current ratio x1.51.31.31.51.3 
Inventory Days Days5564606368 
Debtors Days Days6966687373 
Net fixed assets Rs m3,6944,0224,2965,3076,244 
Share capital Rs m184184184184184 
"Free" reserves Rs m4,3805,0935,5816,3296,566 
Net worth Rs m4,5725,2775,7656,5136,750 
Long term debt Rs m1381293791,3231,233 
Total assets Rs m7,2948,2039,40611,96812,363 
Interest coverage x4.811.49.015.63.1 
Debt to equity ratio x000.10.20.2 
Sales to assets ratio x1.01.01.10.90.8 
Return on assets %10.511.410.07.05.2 
Return on equity %12.715.714.211.86.1 
Return on capital %19.422.218.112.49.0 
Exports to sales %33.936.240.100 
Imports to sales %5.47.57.700 
Exports (fob) Rs m2,4803,1014,04400 
Imports (cif) Rs m39664377300 
Fx inflow Rs m2,4803,1014,0444,5073,762 
Fx outflow Rs m5498191,0171,1411,143 
Net fx Rs m1,9312,2823,0273,3662,619 
INDOCO REMEDIES CASH FLOW
From Operations Rs m 988 1,090 1,122 886 1,227 
From Investments Rs m -410 -884 -1,107 -1,706 -1,360 
From Financial Activity Rs m -590 -199 -16 1,316 -388 
Net Cashflow Rs m -12 7 -1 497 -521 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 59.2%
Foreign collaborators 0.0%
Indian inst/Mut Fund 12.5%
FIIs 6.0%
ADR/GDR 0.0%
Free float 22.4%
Shareholders 12,805
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 166, Indoco House, CST Road, kalina, Santacruz (E), Mumbai - 400 098
E-MAIL sunil.joshi@indoco.com WEB www.indoco.com
TELEPHONE (022) 2654 1851 FAX (022) 2652 3067
SECTOR MISCELLANEOUS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Patkar & Pendse
CHM: Suresh G. Kare (MD) COMP SEC: Sunil D. Joshi YEAR OF INC: 1945 BSE CODE: 532612 FV (Rs): 2 DIV YIELD (%): 0.3

Read: INDOCO REMEDIES 2017-18 Annual Report Analysis

More Miscellaneous Company Fact Sheets:   J.B.CHEMICALS  GLENMARK PHARMA  BIOCON   NOVARTIS  FULFORD INDIA  

Compare INDOCO REMEDIES With:   J.B.CHEMICALS  GLENMARK PHARMA  BIOCON   NOVARTIS  FULFORD INDIA  

Compare INDOCO REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  




Today's Market

Tata Consumer March Quarter Results, M&M's Advanced Design Centre, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended higher on Friday. Benchmark indices edged higher tracking gains in index majors HDFC twins and positive cues from global markets.

Views on news

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

INDOCO REMEDIES Announces Quarterly Results (3QFY20); Net Profit Up 74.9% (Quarterly Result Update)

Jan 27, 2020 | Updated on Jan 27, 2020

For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps? (Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners (Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away? (Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - JSW HOLDINGS COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS